Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 4/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 2/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500609 | 0.93 | DCTPP1 (0.38) | DCTPP1THRBKMT2APIK3C2BTP53 | |
| SCHEMBL6491725 | 0.92 | PIK3C2B (0.37) | DCTPP1PIK3C2BBCL2MCL1 | |
| SCHEMBL6490267 | 0.91 | BCL2 (0.38) | DCTPP1THRBKMT2ATP53MAPT | |
| SCHEMBL6489544 | 0.86 | BCL2 (0.45) | PIK3C2BTP53BCL2MCL1HTT | |
| SCHEMBL6503787 | 0.86 | PIK3C2B (0.38) | DCTPP1PIK3C2BBCL2MCL1 | |
| SCHEMBL6492258 | 0.85 | ALDH1A1 (0.35) | DCTPP1THRBKMT2APIK3C2BTP53 | |
| SCHEMBL6495279 | 0.84 | MAPT (0.36) | DCTPP1THRBPIK3C2BTP53MAPT | |
| SCHEMBL7191818 | 0.84 | DCTPP1 (0.35) | DCTPP1PIK3C2B | |
| SCHEMBL6499279 | 0.84 | BCL2 (0.38) | DCTPP1KMT2APIK3C2BTP53MAPT | |
| SCHEMBL6487607 | 0.82 | REN (0.38) | DCTPP1PIK3C2BBCL2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | DCTPP1 1534/4885THRB 2919/4885KMT2A 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.